Why the study?
Do aldosterone antagonists reduce cardiovascular events and progression of chronic kidney disease in patients with cardiorenal disease?
Do aldosterone antagonists reduce cardiovascular events and progression of chronic kidney disease in patients with cardiorenal disease?
This review highlights the pathophysiological role of aldosterone in cardiorenal disease and the therapeutic potential of aldosterone antagonists in mitigating cardiovascular and renal injury.
Answers are grounded in this paper and cite their sources.
Supports hypothesis of cardiorenal benefit from aldosterone antagonists; leaves open confirmation in prospective outcome trials.
Aldosterone has recently been recognized as an important factor in the development and progression of cardiorenal disease. Animal and human data suggest that aldosterone contributes importantly to several disease states. These include congestive heart failure, coronary heart disease and progression of kidney disease. Recently, the discovery that aldosterone antagonists decrease pathologic injury in the kidneys and nonepithelial tissues, such as the myocardium and endothelium, has generated great controversy regarding the actual mechanisms of benefit of these agents. The available data is reviewed and conclusions drawn regarding the relative benefits of modulating aldosterone effects in the cardiovascular system and the kidney. In particular, the authors review their effects on reductions in cardiovascular events and progression of chronic kidney disease, as well as the safety and tolerability of these agents.
No takes yet. Share an insight, caveat, or question.
Coca et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: